NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.12), Morningstar.com reports. The business had revenue of $1.49 million for the quarter.
NovaBay Pharmaceuticals stock traded down $0.03 during mid-day trading on Friday, reaching $0.39. The company had a trading volume of 406,700 shares, compared to its average volume of 271,907. NovaBay Pharmaceuticals has a 52 week low of $0.23 and a 52 week high of $3.74.
NBY has been the subject of several recent analyst reports. HC Wainwright downgraded shares of NovaBay Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.50 price objective for the company. in a report on Wednesday, March 13th. Zacks Investment Research raised shares of NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating and set a $1.50 price objective for the company in a report on Thursday, March 14th. Finally, Laidlaw downgraded shares of NovaBay Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Featured Article: Analyzing a company’s cash flow statement
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.